ES2545795T3 - Inhibidores del deterioro cognitivo - Google Patents
Inhibidores del deterioro cognitivo Download PDFInfo
- Publication number
- ES2545795T3 ES2545795T3 ES10762322.5T ES10762322T ES2545795T3 ES 2545795 T3 ES2545795 T3 ES 2545795T3 ES 10762322 T ES10762322 T ES 10762322T ES 2545795 T3 ES2545795 T3 ES 2545795T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- haloalkyl
- heteroaryl
- cycloalkyl
- arylalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000028698 Cognitive impairment Diseases 0.000 title 1
- 208000010877 cognitive disease Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract description 67
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract description 66
- 150000003839 salts Chemical class 0.000 abstract description 47
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract description 34
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract description 33
- 125000000217 alkyl group Chemical group 0.000 abstract description 22
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract description 19
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract description 14
- 125000001424 substituent group Chemical group 0.000 abstract description 12
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract description 9
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract description 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 6
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract description 4
- -1 C3- cycloalkyl 7 Chemical compound 0.000 abstract description 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 33
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 28
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 25
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 24
- 125000003118 aryl group Chemical group 0.000 abstract 20
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 20
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 abstract 20
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 16
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 12
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 12
- 125000005843 halogen group Chemical group 0.000 abstract 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 8
- 125000003545 alkoxy group Chemical group 0.000 abstract 7
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 description 64
- 125000001188 haloalkyl group Chemical group 0.000 description 18
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 14
- 238000000034 method Methods 0.000 description 9
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 230000003750 conditioning effect Effects 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 3
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 229940117916 cinnamic aldehyde Drugs 0.000 description 2
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- MZSAMHOCTRNOIZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylaniline Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(NC2=CC=CC=C2)C=CC=1 MZSAMHOCTRNOIZ-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000010649 ginger oil Substances 0.000 description 1
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 1
- 235000002780 gingerol Nutrition 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003141 primary amines Chemical group 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000003335 secondary amines Chemical group 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea group Chemical group NC(=S)N UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/10—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US309091P | 2001-07-31 | ||
| US16798409P | 2009-04-09 | 2009-04-09 | |
| US167984P | 2009-04-09 | ||
| US30866710P | 2010-02-26 | 2010-02-26 | |
| US308667P | 2010-02-26 | ||
| US30909110P | 2010-03-01 | 2010-03-01 | |
| PCT/US2010/030130 WO2010118055A1 (en) | 2009-04-09 | 2010-04-06 | Inhibitors of cognitive decline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2545795T3 true ES2545795T3 (es) | 2015-09-15 |
Family
ID=42936539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10762322.5T Active ES2545795T3 (es) | 2009-04-09 | 2010-04-06 | Inhibidores del deterioro cognitivo |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US8765816B2 (enExample) |
| EP (1) | EP2416795B1 (enExample) |
| JP (1) | JP2012523418A (enExample) |
| CN (2) | CN102458435A (enExample) |
| AU (2) | AU2010234518A1 (enExample) |
| BR (1) | BRPI1007624A2 (enExample) |
| DK (1) | DK2416795T3 (enExample) |
| ES (1) | ES2545795T3 (enExample) |
| IL (1) | IL215645A0 (enExample) |
| RU (1) | RU2595720C2 (enExample) |
| SG (2) | SG176772A1 (enExample) |
| WO (1) | WO2010118055A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI1007624A2 (pt) | 2009-04-09 | 2016-07-26 | Cognition Therapeutics Inc | composto, método para preparar uma composição, composto ou sal farmaceuticamente aceitável deste e uso de um composto ou um sal farmaceuticamente aceitável deste |
| CN102595884B (zh) | 2009-07-31 | 2014-12-03 | 考格尼申治疗股份有限公司 | 认知衰退的抑制剂 |
| AU2012212219B2 (en) | 2011-02-02 | 2017-03-23 | Cognition Therapeutics, Inc. | Isolated compounds from turmeric oil and methods of use |
| JP2014529613A (ja) * | 2011-08-25 | 2014-11-13 | コグニションセラピューティクス，インコーポレイテッド | 神経変性疾患を治療する組成物及び方法 |
| EP2747759A4 (en) * | 2011-08-25 | 2015-05-13 | Cognition Therapeutics Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES |
| CN104220421A (zh) | 2012-03-20 | 2014-12-17 | 阿达梅德公司 | 用于治疗中枢神经系统疾病的苄胺的磺酰胺衍生物 |
| ES2769780T3 (es) | 2013-10-28 | 2020-06-29 | Univ Drexel | Tratamientos novedosos para los trastornos de atención y cognitivos y para la demencia asociada a un trastorno neurodegenerativo |
| DK3498692T3 (da) | 2014-01-31 | 2022-05-16 | Cognition Therapeutics Inc | Isoindolin-sammensætninger og fremgangsmåder til behandling af neurodegenerativ sygdom og makulær degeneration |
| BR112019023851A2 (pt) | 2017-05-15 | 2020-08-18 | Cognition Therapeutics, Inc. | compostos, suas composições farmacêuticas e métodos para tratamento de doenças neurodegenerativas |
| WO2021055670A1 (en) | 2019-09-20 | 2021-03-25 | Avx Corporation | Somatic cell-based electrical biosensor |
| US20230190870A1 (en) | 2020-05-20 | 2023-06-22 | The Board Of Trustees Of The University Of Illinois | Method for Treating Lysosomal Storage Diseases with Histatin Peptides |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4321386A (en) * | 1981-01-28 | 1982-03-23 | Mead Johnson & Company | Quaternary piperidinium halides |
| JPS62283922A (ja) * | 1986-05-30 | 1987-12-09 | Tsumura Juntendo Inc | 血小板凝集抑制剤 |
| US4697024A (en) | 1986-11-24 | 1987-09-29 | Merrell Dow Pharmaceuticals Inc. | Medroxalol intermediates |
| JPH01180822A (ja) * | 1988-01-12 | 1989-07-18 | Dainippon Pharmaceut Co Ltd | 抗遅延型アレルギー剤 |
| EP0507863A4 (en) | 1989-12-28 | 1993-07-07 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
| DE4000610A1 (de) | 1990-01-11 | 1991-07-18 | Knoll Ag | Verfahren zur herstellung von optisch aktiven 3-amino-1-arylbutanen und 3-benzylamino-1-arylbutanen |
| JP2818958B2 (ja) * | 1990-02-23 | 1998-10-30 | 塩野義製薬株式会社 | ４―（４―アルコキシフェニル）―２―ブチルアミン誘導体およびその製造法 |
| DE4142366A1 (de) | 1991-07-15 | 1993-06-24 | Thomae Gmbh Dr K | Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| US6011068A (en) * | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| PT724561E (pt) * | 1991-08-23 | 2004-07-30 | Nps Pharma Inc | Arilalquil-aminas como receptores activos de calcio |
| CN1093079A (zh) * | 1993-03-30 | 1994-10-05 | 陈英俊 | 由具有愈创木酚结构之香辛类化合物及其去氢化合物衍生之肾上腺素激性乙型阻断剂 |
| WO1996012697A2 (en) * | 1994-10-21 | 1996-05-02 | Nps Pharmaceuticals, Inc. | Calcium receptor-active compounds |
| EP0881220A4 (en) | 1996-02-15 | 1999-04-21 | Mitsubishi Chem Corp | DIARYLSULTAME DERIVATIVES |
| US6518315B1 (en) | 1997-10-21 | 2003-02-11 | The University Of Sydney | Medicinal uses of phenylaikanols and derivatives |
| NZ516888A (en) * | 1999-07-30 | 2004-02-27 | Vertex Pharma | Acyclic and cyclic amine derivatives |
| WO2001030335A2 (en) | 1999-10-22 | 2001-05-03 | The Board Of Trustees Of The University Of Illinois | Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease |
| JP4312402B2 (ja) | 2001-07-31 | 2009-08-12 | 有限会社大長企画 | 抗うつ剤、抗更年期障害剤、抗老人性痴呆症剤、抗アルツハイマー剤 |
| AU2002332659A1 (en) * | 2001-08-21 | 2003-03-03 | Sepracor, Inc. | 2-substituted piperidines that are ligands for monoamine receptors and transporters |
| US6991814B2 (en) | 2001-12-13 | 2006-01-31 | Council Of Scientific And Industrial Research | Herbal medicaments for the treatment of neurocerebrovascular disorders |
| JP2004002517A (ja) * | 2002-05-31 | 2004-01-08 | Dae Sil Kim | 生姜成分を含む石鹸の組成物及びその製造方法 |
| DE10320560A1 (de) | 2003-05-07 | 2004-01-29 | Brosig, Stefan, Dr. | Mittel zur Bekämpfung der Alzheimer Erkrankung und/oder der Parkinson Krankheit |
| WO2004110389A2 (en) | 2003-06-12 | 2004-12-23 | Agy Therapeutics, Inc. | Sigma ligands for neuronal regeneration and functional recovery |
| CA2571614C (en) | 2004-06-21 | 2016-12-06 | Proteome Sciences Plc | Screening methods |
| TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| US20080153917A1 (en) | 2004-09-10 | 2008-06-26 | Ucb Pharma, S.A. | Sigma Receptor Ligands |
| GB0423356D0 (en) * | 2004-10-21 | 2004-11-24 | Merck Sharp & Dohme | Therapeutic agents |
| ATE458754T1 (de) | 2005-03-05 | 2010-03-15 | Abbott Gmbh & Co Kg | Screening-verfahren, verfahren zur aufreinigung nichtdiffundierbarer a-beta-oligomere, selektive antikörper gegen diese nichtdiffundierbaren a- beta-oligomere und verfahren zur herstellung dieser antikörper |
| KR20080041624A (ko) | 2005-06-15 | 2008-05-13 | 대릭 에스. 에치. 엘. 김 | 베타-아밀로이드 단백질-유발 안질환의 치료 방법 |
| US20070021413A1 (en) | 2005-07-20 | 2007-01-25 | Peter Herold | Diamino alcohols as therapeutic compounds |
| ITRM20060007A1 (it) | 2006-01-05 | 2007-07-06 | Univ Bari | Recettore sigma-2 metodo di screening di ligandi specifici e uso degli stessi in metodi diagnostici o terapeutici |
| WO2007109210A2 (en) | 2006-03-17 | 2007-09-27 | Herbalscience Singapore Pte. Ltd. | Extracts and methods comprising curcuma species |
| US20100029654A1 (en) | 2006-03-23 | 2010-02-04 | Mount Sinai School Of Medicine | Cardiovascular compositions and use of the same for the treatment of alzheimer's disease |
| US7561775B2 (en) | 2006-08-22 | 2009-07-14 | Senko Advanced Components, Inc. | Fiber optic protective shutter |
| WO2008042755A2 (en) | 2006-09-29 | 2008-04-10 | Cognition Therapeutics, Inc. | Inhibitors of cognitive decline |
| US20100028333A1 (en) | 2006-12-15 | 2010-02-04 | Getty Krista L | Receptor for amyloid beta and uses thereof |
| AU2008254905A1 (en) | 2007-05-15 | 2008-11-27 | Helicon Therapeutics, Inc. | Methods of treating cognitive disorders by inhibition of Gpr12 |
| US8304547B2 (en) * | 2007-10-24 | 2012-11-06 | Astellas Pharma Inc. | Azolecarboxamide compound or salt thereof |
| WO2009059214A1 (en) | 2007-11-02 | 2009-05-07 | The Regents Of The University Of California | Abeta-binding small molecules |
| KR101515822B1 (ko) | 2008-11-29 | 2015-04-29 | 더 타일랜드 리서치 펀드 | 바이러스와 타겟 세포의 상호작용 저해 |
| BRPI1007624A2 (pt) | 2009-04-09 | 2016-07-26 | Cognition Therapeutics Inc | composto, método para preparar uma composição, composto ou sal farmaceuticamente aceitável deste e uso de um composto ou um sal farmaceuticamente aceitável deste |
| CN102595884B (zh) | 2009-07-31 | 2014-12-03 | 考格尼申治疗股份有限公司 | 认知衰退的抑制剂 |
| US20130071330A1 (en) | 2010-02-26 | 2013-03-21 | Susan Catalano | Methods of identifying agents effective to treat cognitive decline and diseases associated therewith |
| EP2747759A4 (en) | 2011-08-25 | 2015-05-13 | Cognition Therapeutics Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES |
-
2010
- 2010-04-06 BR BRPI1007624A patent/BRPI1007624A2/pt not_active Application Discontinuation
- 2010-04-06 WO PCT/US2010/030130 patent/WO2010118055A1/en not_active Ceased
- 2010-04-06 CN CN2010800257716A patent/CN102458435A/zh active Pending
- 2010-04-06 DK DK10762322.5T patent/DK2416795T3/en active
- 2010-04-06 EP EP10762322.5A patent/EP2416795B1/en active Active
- 2010-04-06 ES ES10762322.5T patent/ES2545795T3/es active Active
- 2010-04-06 JP JP2012504788A patent/JP2012523418A/ja active Pending
- 2010-04-06 CN CN201610113476.5A patent/CN105968022A/zh active Pending
- 2010-04-06 US US13/263,162 patent/US8765816B2/en active Active
- 2010-04-06 AU AU2010234518A patent/AU2010234518A1/en not_active Abandoned
- 2010-04-06 SG SG2011091352A patent/SG176772A1/en unknown
- 2010-04-06 RU RU2011145321/04A patent/RU2595720C2/ru not_active Application Discontinuation
- 2010-04-06 SG SG10201404913QA patent/SG10201404913QA/en unknown
-
2011
- 2011-10-09 IL IL215645A patent/IL215645A0/en unknown
-
2014
- 2014-06-02 US US14/293,755 patent/US9365491B2/en active Active
-
2015
- 2015-10-12 AU AU2015242954A patent/AU2015242954B2/en not_active Ceased
-
2016
- 2016-06-13 US US15/181,211 patent/US20160355458A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010118055A1 (en) | 2010-10-14 |
| AU2015242954B2 (en) | 2016-08-25 |
| US20160355458A1 (en) | 2016-12-08 |
| SG176772A1 (en) | 2012-01-30 |
| DK2416795T3 (en) | 2015-08-31 |
| CN105968022A (zh) | 2016-09-28 |
| SG10201404913QA (en) | 2014-11-27 |
| HK1167323A1 (en) | 2013-01-04 |
| BRPI1007624A2 (pt) | 2016-07-26 |
| AU2015242954A1 (en) | 2015-10-29 |
| EP2416795A1 (en) | 2012-02-15 |
| US8765816B2 (en) | 2014-07-01 |
| US20120095105A1 (en) | 2012-04-19 |
| IL215645A0 (en) | 2012-01-31 |
| EP2416795A4 (en) | 2013-12-25 |
| CN102458435A (zh) | 2012-05-16 |
| RU2595720C2 (ru) | 2016-08-27 |
| JP2012523418A (ja) | 2012-10-04 |
| EP2416795B1 (en) | 2015-06-03 |
| RU2011145321A (ru) | 2013-05-20 |
| US20140371324A1 (en) | 2014-12-18 |
| US9365491B2 (en) | 2016-06-14 |
| AU2010234518A1 (en) | 2012-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2545795T3 (es) | Inhibidores del deterioro cognitivo | |
| ES2630115T3 (es) | Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina con sulfoximina sustituida y su uso como inhibidores de quinasa cdk9 | |
| ES2671343T3 (es) | Procesos para la síntesis de compuestos de diariltiohidantoína y diarilhidantoína | |
| ES2779225T3 (es) | Reactivos de merilformilo sustituido y procedimiento de uso de los mismos para modificar propiedades fisicoquímicas y/o farmacocinéticas de compuestos | |
| ES2899694T3 (es) | Compuestos novedosos, su síntesis y sus usos | |
| CA2998875C (en) | Carborane compounds and methods of use thereof | |
| ES2319024A1 (es) | Procedimiento para la obtencion de entacapona sustancialmente libre de sisomero, z, sus intermedios de sintesis y nueva forma cristalina. | |
| HRP20020559A2 (en) | Novel esters derived from (rr,ss)-2-hydroxybenzoate of 3-(2-dimethylaminomethyl-1-hydroxycyclohexyl)phenyl | |
| ES2449774T3 (es) | Un método para la preparación de folatos marcados con 18F | |
| KR930016389A (ko) | No 신타제 및 시클로옥시게나제의 이중 억제제, 이들의 제조방법 및 이들을 함유하는 치료 조성물 | |
| CA3113226A1 (en) | Antibacterial compounds | |
| ES2924995T3 (es) | Procedimiento industrial para la preparación de cariprazina | |
| TW201524983A (zh) | 螺氧基吲哚衍生物之製造方法 | |
| ES2704951T3 (es) | Compuesto precursor de marcaje radioactivo y método para producir un compuesto marcado con flúor radioactivo utilizando el compuesto precursor | |
| CN103108861A (zh) | 神经氨酸酶抑制剂 | |
| ES2456866T3 (es) | Procedimiento para la obtención de 3,3-difenilpropilaminas | |
| AU2023356963A1 (en) | Cereblon-recruiting bcl-xl/bcl-2 dual degraders | |
| US7745480B2 (en) | Deuterium-enriched atorvastatin | |
| US20170001957A1 (en) | Radioiodinated bioconjugation reagents | |
| RU2002113374A (ru) | Способ получения (E)-N-метил-N-(1-нафтилметил)-6,6-диметилгепт-2-ен-4-инил-1-амина или его кислотно-аддитивной соли | |
| CN110483417B (zh) | 一种DACOs类NNRTIs氨基酸酯衍生物、其制备方法、药物组合物及应用 | |
| da Silva et al. | Natural occurrence, synthesis and biological applications of spermidine alkaloids | |
| CN101239915A (zh) | β-榄香烯单取代胺衍生物及其合成方法和应用 | |
| ES2312749T3 (es) | Aminas fenilpirimidina como inhibidores de ige. | |
| CN109422798A (zh) | 一种苯基丙酰胺类衍生物的游离碱晶型及其制备方法 |